CRITIC - Treatment of Candidemia and Invasive Candidiasis

Inclusion Criteria: * Patients admitted to ICU for all medical reasons that meet the inclusion criteria * Males or non pregnant females (women of child-bearing potential must have a negative serum or urine pregnancy test at baseline). * Subjects who are 14 years old or older. * Subjects with at least one positive blood culture isolation of a Candida spp. from a specimen or from a normally sterile site (including abdominal catheters), drawn within 96 hours prior to study entry. * Subjects who have clinical evidence of infection AT SOME TIME WITHIN 48 HOURS PRIOR TO ENROLLMENT, including AT LEAST ONE of the following: 1. temperature\> 38°C on 2 occasions at least 4 hours apart or one determination greater than 38.5°C (internal, at oesophagus, tympani or bladder levels). 2. systolic blood pressure \< 90, or a \>30 mm Hg decrease in systolic BP from the subject's normal baseline. 3. Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida * Subjects or their legal representative (but the subject should sign it in any case when able to) must sign a written informed consent form. Written informed consent must be obtained before any study-related procedure is carried out. Exclusion Criteria: * Subjects with a history of allergy or intolerance to AmBisome® * Subjects who have received systemic antifungal therapy within 15 days prior to inclusion in the study * Any severe cardiovascular disease (such as arrhythmias, in particular) which may constitute a contra-indication to AmBisome® administration * Subjects with an absolute neutrophil count of less than 500/mm3 in the 48 hours before enrolment in the study * Subjects with a diagnosis of AIDS (positive HIV serology in association with either CD4 cell counts \< 200 cells/mm3or history of an opportunistic infection /neoplasm), aplastic anemia, or Chronic Granulomatous Disease. * Subjects with moderate or severe liver disease defined as any one or more of the following: \* Alkaline phosphatase, ALT, AST, or total bilirubin greater than 5 times the ULN (upper limit of normal) * Subjects with a severe renal impairment defined by a serum creatinine of more than 2.5 mg/dL. * Women who are pregnant or breastfeeding. * Subjects who are unlikely to survive more than 24 hours. * Subjects who previously participated in this study. * Subjects who have received within the two weeks before study entry, are receiving or likely to receive any investigational drug (unlicensed new chemical entity).